

Contents lists available at ScienceDirect

IJC Heart & Vasculature



journal homepage: http://www.journals.elsevier.com/ijc-heart-and-vasculature

Frailty is independently associated with 1-year mortality after hospitalization for acute heart failure



Diego Costa *, Martín Aladio, Camilo A. Girado, Ricardo Pérez de la Hoz, C. Sara Berensztein

Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires, Argentina

A R T I C L E I N F O

Introducti

Article history: Received 4 September 2018 Received in revised form 7 October 2018 Accepted 10 October 2018 Available online 7 November 2018

Keywords: Frailty Heart failure Acute heart failure 1-year mortality Elderly CFS

ABSTRACT

Introduction: Frailty is a complex condition that results from the loss of physiological reserve across multiple systems. Its presence should be considered in the aging heart failure population, since it is an important predictor of death and institutionalization in the elderly.

Methods and results: In a prospective, observational and analytical single-center study of 100 elderly patients hospitalized for acute heart failure, we assessed the characteristics associated with an increased hospital and 1-year mortality. Frailty was evaluated with the Clinical Frailty Scale, and there was a significant association between its presence and 1-year mortality (RR = 2.03; 95% CI = 1.18–3.48; p = 0.014), although not with in-hospital mortality. After adjusting for probable confounders, it remained independently associated with 1-year mortality. *Conclusion:* Frailty can be assessed with a simple bed-side scale and provides significant prognostic information in acute heart failure patients.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Heart failure (HF) is a global pandemic: according to some estimations, it affects around 26 million people worldwide [1]. Also, its prevalence grows continuously. For instance, in the US a 46% increase in its prevalence is expected by 2030 [2]. On the other hand, HF incidence is reported to be stable or even decreasing in several studies [3]. This could be explained by more accessible and effective treatment, and an extended life span of the population. We may anticipate, with some confidence, a drastic change in the demographic characteristics of HF patients in the future. They will be older and have more comorbidities as well as being frailer.

Frailty is a complex condition that results from the loss of physiological reserve across multiple systems. It manifests clinically as an increased vulnerability to adverse outcomes when faced to disease or even mild stress [4]. Frailty acts as a marker of biological age and is more closely associated with prognosis than chronological age [5]. In the Canadian Study of Health and Aging, it was the most important predictor of death and institutionalization with an odds ratio (OR) of 7.28 and 95% confidence interval (CI) of 5.01–10.58 among mildly frail people and 8.64 (95% CI = 4.92–15.17) among severely frail people [6].

Unfortunately, there is no universal method for measuring frailty. Two approaches summarize the multiple scales and definitions used across clinical studies: the frailty phenotype and the geriatric assessment. The former was developed and validated by Fried and colleagues in the Cardiovascular Health Study and describes a patient as being frail when three or more features are present from five specific measures: unintentional weight loss, exhaustion, slow walking speed, weakness and low physical activity [7]. The latter is a more holistic approach that involves the inclusion of four validated geriatric tools to assess domains of functional autonomy, cognitive deterioration, emotional disturbances and social risk [8]. Both are time-consuming and require special knowledge or instruments and would encounter resistance for application in every-day practice. There have been attempts to simplify frailty determination, such as the Clinical Frailly Scale (CFS), which correlates well with the Frailty Index [9].

The presence of frailty should be considered in the aging HF population, and it was investigated to some extent. It was shown to occur frequently in patients with HF, with a prevalence ranging from 15 to 74%, depending on the studied population and the method of assessment [10]. Also, it is associated with adverse outcomes during hospitalization, as well as events in the short and long term [11–14]. Despite its importance, it is not accounted for in any prognostic score for HF as the MAGGIC score or the Seattle Heart Failure Model [15,16], and no frailty scales have been specifically validated for HF.

We proposed in this study to determine the performance of a simple and well-validated bed-side frailty scale to predict 1-year mortality in elderly patients admitted for acute HF in a tertiary hospital.

2. Methods

* Corresponding author. *E-mail address:* diegosta@gmail.com (D. Costa). We conducted a prospective, observational and analytical singlecenter study in a University Hospital in Buenos Aires, Argentina. We

https://doi.org/10.1016/j.ijcha.2018.10.004

2352-9067/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

screened all hospitalizations with a primary diagnosis of acute heart failure from June 1, 2016 to May 31, 2017, both in the general ward or in the Coronary Care Unit. All patients who gave their consent to participate were included in this study, following the principles of the Declaration of Helsinki and local regulation for protection of medical data. The study protocol was approved by the Bioethics Committee of the Hospital.

Patient's age, sex, and clinical data were obtained from the medical history. Comorbidities, previous medical treatment, and NYHA (New York Heart Association) class were recorded. The cause of decompensation and in-hospital medical treatment were evaluated, as well as left ventricle ejection fraction if an echocardiogram was performed. Patients were called by telephone 1 year after the hospitalization to determine their vital status or rehospitalization. When it was not possible to reach them or their next of kin, hospital records were reviewed.

Frailty was assessed be means of the CFS. This semi-quantitative instrument classifies patients into 9 categories, where 1 is the least frail and 9 is the frailest (Fig. 1). Patients were then divided into non-frail with a score of 4 or less, or frail with a score of 5 or more.

The primary end-point was 1-year mortality. In-hospital mortality and readmission rates were analyzed as secondary endpoints.

Sample-size calculations showed that 102 hospitalizations would be necessary to achieve an 80% power to detect a 25% difference in the primary end-point. Based on previous hospital statistics, we estimated that this amount of hospitalizations could take place within 1 year. The variables are presented as mean and standard deviation $(\pm SD)$ or frequencies. A two-sided *t*-test was used to compare continuous variables if normally distributed, or a Wilcoxon test if not normally distributed. For categorical variables, chi-square test or Fisher's test were used, respectively. A logistic multivariate regression model was used to assess 1-year mortality in frail or non-frail patients adjusting for baseline clinical characteristics. All calculations were done with STATA v11.1. Statistical significance was considered if the *p*-value was <0.05.

beyond routine walking.

during the day.

and housework.

standby) with dressing.

Clinical Frailty Scale*

exercise or are very active occasionally, e.g. seasonally.

3 Managing Well – People whose medical problems are well controlled, but are not regularly active

4 Vulnerable – While not dependent on others for daily help, often symptoms limit activities. A common complaint is being "slowed up", and/or being tired

5 Mildly Frail - These people often have more

evident slowing, and need help in high order IADLs

(finances, transportation, heavy housework, medica-

shopping and walking outside alone, meal preparation

tions). Typically, mild frailty progressively impairs

6 Moderately Frail – People need help with all outside activities and with keeping house. Inside, they

often have problems with stairs and need help with

bathing and might need minimal assistance (cuing,


3. Results

There were 101 hospitalizations with a primary diagnosis of heart failure from June 1, 2016 to May 31, 2017. Only 1 patient declined to participate in this study. The mean age was 77 ± 13.4 years, 56% were men and 86% were admitted to the general ward. 41% had an ejection fraction of the left ventricle of <40%. Most patients had some risk factor or comorbidity: 78% were hypertensive, 52% had chronic heart failure (60% in NYHA class II and 26% in class III), 23% had coronary disease, 36% were diabetic, 33% had atrial fibrillation, 24% had chronic renal disease and 24% had COPD. The most frequent causes for decompensation were disease progression (22%), infection (19%), atrial supraventricular tachycardia (15%), and non-adherence to diet (11%). All baseline characteristics and outcomes are presented in Table 1.

The total mortality rate was 10.20% for in-hospital deaths and 40.96% after 1 year of follow-up, with complete data for 83 patients.

Frailty was present in 28% of the patients, according to the CSF. It was not associated with in-hospital mortality (RR = 1.04; 95% CI = 0.22–5.02; p = 0.96). There was a significant association between frailty and 1-year mortality (RR = 2.03; 95% CI = 1.18–3.48; p = 0.014). Frail patients had a 59.09% 1-year mortality, while for non-frail patients it was 29.09% (p = 0.014). 1-year mortality according to the CFS can be visualized in Fig. 2.

Finally, we constructed a logistic regression model with a forwardselection stepwise approach. The variables significantly associated with an increase in 1-year mortality in the final model were frailty, advanced age, increased heart rate at admission, history of dyslipidemia, COPD or peripheral artery disease, reduced blood sodium level, and treatment with furosemide. Treatment with aspirin, beta blockers, calcium channel blockers and aldosterone antagonists showed a protective effect. Frailty assessed by means of the CFS was therefore significantly and independently associated with 1-year mortality (OR 2.97; 95% CI = 1.16–7.59; p = 0.023, Fig. 3 [17]).



7 Severely Frail – Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).

8 Very Severely Frail – Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.



9 Terminally III - Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.</p>

Scoring frailty in people with dementia

The degree of frailty corresponds to the degree of dementia. Common symptoms in mild dementia include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.

In moderate dementia, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In severe dementia, they cannot do personal care without help.

* 1. Canadian Study on Health & Aging, Revised 2008.

2. K. Rockwood et al. A global clinical measure of fitness and

frailty in elderly people. CMAJ 2005;173:489-495.

Fig. 1. Clinical frailty scale. ©2007–2009 Version 1.2. All rights reserved. Geriatric Medicine Research, Dalhousie University, Halifax, Canada. Permission granted to copy the Clinical Frailty Scale for research and educational purposes only.

Table 1	
Baseline characteristics of the population.	

Age MalesTotal (n = 26)Non-frail (n = 66)Age Males77 ± 13.480 ± 11.371 ± 13.6HistoryHypertension78%75.76%88.46%Diabetes36%30.77%23.08%28.79%Smokers27%23.08%28.79%23.08%28.79%Diabetes27%23.08%28.79%23.08%28.79%Dyslipdemia7%7%11.54%6.06%Coronary disease23%19.23%24.24%Chronic Heart failure52%69.23%43.94%Ejection fraction <40%51%35.29%53.36%Peripheral artery disease24%19.23%22.73%Stroke4%7.69%30.30%47.41 fbrillationAtrial fbrillation33%4.62%30.30%Atrial fbrillation33%34.62%30.30%Atrial fbrillation33%4.62%30.30%Atrial fbrillation33%4.62%30.30%Atrial fbrillation32%23.08%36.36%Kasis35%30.30%34.62%30.30%Atrial fbrillation32%24.24%30.30%Mineralocorticoid receptor10%11.54%9.09%Agirin32%23.28%36.36%Statins35%36.36%36.36%Anticoagulants27%26.92%27.27%Non-adherence to diet11%4.17%10.17%Anticoagulants27%38.36%10.61%Non-a	Variable		Mean or frequency			
nnnnnnnAge MalesHypertension78, 750, 30, 77, 411, 13, 6HistoryHypertension78, 75, 76, 88, 46, 37, 75, 7888, 46, 37, 78, 78, 78, 78, 78, 78, 78, 78, 78, 7			Total	Frail	Non-frail	
Age 77 ± 13.4 80 ± 11.3 71 ± 13.6 Males 56% 30.77% 62.12% History Hypertension 78% 75.76% 88.46% Smokers 23% 19.23% 22.73% Dyslipidemia 7% 7.69% 7.58% Obesity 7% 15.44 6.06% Coronary disease 23% 19.23% 22.73% Dyslipidemia 7% 7.69% 7.58% Obesity 7% 11.54% 6.06% Coronary disease 5% 0% 6.06% Peripheral artery disease 5% 0% 6.06% Stroke 4% 7.69% 3.03% Atrial fibrillation 33% 34.62% 30.3% Medication ACE inhibitors 36% 38.46% 36.36% Glacium channel blockers 10% 7.227% 30.77% 27.27% Mineralocorticoid receptor 11% 41.67% 13.64% 36.36% Furosemide 49						
Males56%30.77%62.12%HistoryHypertension78%75.76%88.46%Diabetes36%34.62%40.91%Smokers27%23.08%28.79%Pormer smokers23%19.23%22.73%Dyslipidemia7%7.69%7.58%Obesity7%11.54%6.06%Cronary disease23%19.23%24.24%Chronic Heart failure52%69.23%43.94%Ejection fraction <40%	A ===		77 + 12.4	, ,	71 + 12 C	
HistoryHypertension78%75.76%88.46%Diabetes36%34.62%40.91%Diabetes36%34.62%40.91%Smokers23%19.23%22.73%Dyslipidenia7%7.69%7.58%Obesity7%11.54%6.06%Coronary disease23%19.23%22.43%Ejection fraction <40%						
Diabetes36%34.62%40.91%Smokers27%23.08%28.79%Former smokers23%19.23%22.73%Dyslipidemia7%7.69%7.58%Obesity7%11.54%6.06%Coronary disease23%19.23%24.24%Chronic Heart failure52%69.23%43.94%Ejection fraction <40%		Unportancian				
Smokers27%23.08%28.79%Former smokers23%19.23%22.73%Dysipidemia7%11.54%6.06%Obesity7%11.54%6.06%Coronary disease23%19.23%24.24%Chronic Heart failure52%69.23%43.94%Ejection fraction ~40%51%35.29%55.36%Peripheral artery disease5%0%6.06%Renal disease24%19.23%22.73%Stroke4%7.69%3.03%Attrial fibrillation33%34.62%30.30%OPD07P07%35.75%36.76%Rad disease60%69.23%57.58%MedicationAEE inhibitors24%26.92%Attrial fibrillation32%38.46%36.36%Statins35%32.08%36.36%Statins35%32.08%36.36%Statins35%32.08%36.36%Statins35%36.36%35.36%Statins35%36.36%35.36%Statins35%36.36%35.36%Statins35%36.36%35.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.	riistory					
Former smokers23%19.23%22.73%Dyslipidemia7%7.69%7.58%Obesity7%11.54%6.06%Coronary disease23%19.23%24.24%Ejection fraction ~40%51%35.29%55.36%Peripheral artery disease5%0%6.06%Renal disease24%19.23%22.73%Stroke4%7.69%3.03%Arrial fibrillation33%34.62%30.30%COPD10%11.54%9.09%Pacemaker8%3.85%9.09%MedicationACE inhibitors36%38.46%36.36%ARBs27%30.77%27.27%Beta blockers60%69.23%27.27%Mineralocorticoid receptor12%7.69%13.64%Aspirin32%23.08%36.36%Statins35%38.46%36.36%Furosemide9%11.54%9.09%Anticoagulants27%23.02%27.27%Amiodarone9%11.54%9.09%Digoxin3%38.5%3.03%Decompensation10%1.56%10.17%Infection19%4.17%10.17%Lack of medication9%8.33%3.09%Decompensation0thers9%4.17%15.25%Rand failure5%5.66%10.20%Valvular18%22.22%28.57%NYHA class114%3.55%10.20% <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>						
Pysilpidemia7%7.69%7.58%Obesity7%11.54%6.06%Oronary disease23%19.23%24.24%Chronic Heart failure52%69.23%43.94%Ejection fraction ~40%51%35.29%55.36%Peripheral artery disease7%7.69%3.03%Atrial fibrillation24%19.23%22.73%Stroke4%7.69%3.03%Atrial fibrillation33%34.62%3.030%COPD10%11.54%9.09%Pacemaker8%3.85%9.09%Pacemaker8%3.85%9.09%Pacemaker6%3.636%36.36%ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors12%7.69%13.64%Aprin35%38.46%36.36%Statins35%38.46%36.36%Non-adherence to diet11%41.7%10.17%Lack of medication9%8.33%3.39%Decompensation10%13.56%10.01%Moto13%4.16%15.25%Ronal failure5%8.33%3.39%Decompensation0thers9%4.17%15.25%Mono13%27.27%16.33%16.31%Moto13%3.00%6.556%10.20%Mito13%27.78%16.33%3.39% </td <td></td> <td></td> <td></td> <td></td> <td></td>						
Obesity7%11.54%6.06%Coronary disease23%19.23%24.24%Coronic Heart failure52%69.23%43.94%Ejection fraction <40%						
Coronary disease23%19.23%24.24%Chronic Heart failure52%69.23%43.94%Ejection fraction ~40%51%35.29%55.36%Peripheral artery disease5%0%6.06%Renal disease24%19.23%22.73%Stroke4%7.69%3.03%Atrial fibrillation33%34.62%30.08%COPD10%11.54%9.09%Pacemaker8%3.85%9.09%MedicationAE60%69.23%57.58%Mineralocorticoid receptor24%26.92%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor12%7.69%13.64%Aspirin32%23.08%36.36%Statins35%3.84%36.36%Statins35%3.84%36.36%Statins27%2.692%27.27%Amiodarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%4.15%15.25%Renal failure5%8.33%10.17%Lack of medication9%4.16%15.25%Renal failure5%8.33%3.96%DecompensationOthers9%4.17%13.56%Infection13%2.22.22%2.85%Idiopathic6%5.66%						
Chronic Heart failure52%69.23%43.94%Ejection fraction <40%						
Figure 1Figure 151%55.36%Peripheral attery disease5%0%6.06%Renal disease24%19.23%22.73%Stroke33%44.62%3.03%Atrial fibrillation33%34.62%3.030%OCD10%11.54%9.09%Pacemaker36%38.55%9.09%ACE inhibitors36%38.46%36.36%ARBs27%30.77%27.27%Mineralocorticoid receptor24%26.92%24.24%inhibitors23.08%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%23.02%27.27%Amiodarone9%11.54%909%Digoxin3%38.55%3.03%Progression23%24.24%10.17%Supraventricular11%41.7%10.17%Lack of medication9%41.67%15.25%Non-adherence to diet11%41.7%15.25%Infection19%41.67%15.25%Nender15%41.7%15.25%Nender13%22.23%26.5%Nender13%22.23%26.5%Nender15%41.7%15.25%Nender15%41.6%15.6%Nender<		5				
Peripheral artery disease5%0%6.06%Renal disease24%19.23%22.73%Stroke4%7.69%30.30%Attrial fibrillation33%34.62%30.30%COPD10%11.54%9.09%Pacemaker8%3.846%66.36%CEI inhibitors36%38.46%66.36%ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%23.08%36.36%Statins35%38.46%66.36%Statins35%38.46%66.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amitodarone9%11.54%909%Digoxin3%3.85%3.03%10.17%Lack of medication9%8.35%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%4.16%15.25%Renal failure5%8.33%3.98%Decompensation10%13.56%10.01%Infection13%4.17%13.56%Infection13%27.78%16.33%Valvular18%2.22%28.57%Idiopathic6%5.56%10.20%Valvular13%2.2.2%28.57%Idiopathic6%5.50%10.20%VHers13%5						
Renal disease 24% 19.23% 22.73% Stroke 4% 7.69% 3.03% Atrial fibrillation 33% 34.62% 90.90% Pacemaker 8% 3.85% 90.99% Pacemaker 8% 3.85% 90.99% ACE inhibitors 36% 38.46% 36.36% ARBs 27% 30.77% 27.27% Beta blockers 60% 69.23% 57.58% Mineralocorticoid receptor 24% 26.92% 24.24% inhibitors 12% 7.69% 13.64% Aspirin 32% 23.08% 36.36% Furosemide 49% 42.31% 48.48% Anticoagulants 27% 26.92% 27.27% Amiodarone 9% 11.54% 9.09% Digoxin 3% 3.85% 30.3% 10.17% Lack of medication 1% 4.17% 10.17% Lack of medication 9% 4.167% 15.25% Renal						
Stroke4%7.69%3.03%Atrial fibrillation33%34.62%30.30%COPD10%11.54%9.09%Pacemaker8%3.85%9.09%ACE inhibitors36%38.46%36.36%ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors2%23.08%36.36%Calcium channel blockers12%7.69%13.64%Aspirin32%23.08%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Mindarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Supraventricular15.25%10.61%Infection19%4.16%15.25%Idipathic6%5.56%10.20%Valvular13%2.25%10.20%Valvular13%2.25%10.30%Idiopathic6%5.56%10.20%VHA class19%3.00%8.25%FiologyUnknown30%3.07%2.27%NYHA class16%5.50%10.20%In26%5.00%<						
Atrial fibrillation33%34.62%30.30%COPD10%11.54%9.09%Pacemaker8%3.85%9.09%ACE inhibitors36%38.46%66.36%ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors24%23.08%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amitoagulants27%26.92%27.27%Amitoagulants27%26.92%27.27%Amitoagulants27%26.92%27.27%Non-adherence to diet11%4.17%10.17%Lack of medication9%3.38%303%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%4.17%13.56%Infection19%41.67%15.25%Renal failure5%8.33%3.39%Decompensation0thers9%4.17%13.56%Infection13%2.2.22%28.57%Idiopathic6%5.56%10.20%Valvular13%2.2.28%2.5.5%Idiopathic6%5.50%10.20%VHers <td></td> <td></td> <td></td> <td></td> <td></td>						
MedicationCOPD10%11.54%9.09%MedicationACE inhibitors36%38.45%9.03%ACE inhibitors30%38.46%36.36%ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors21%7.69%13.64%Aspirin32%23.08%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amiodarone9%11.54%9.09%Digoxin3%38.55%30.37%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Supraventricular15%4.17%15.25%Renal failure5%8.33%3.39%Decompensatio0thers9%4.13%15.25%Motive10%13.56%10.61%Ischemic37%38.89%32.65%Chagas6%5.56%10.20%Valvular18%22.22%28.57%Ifi6%5.56%10.20%Valvular13%27.78%16.33%EtiologyUnknown30%30.77%27.27%NYHA classI6%5.50%10.20%Ifi6%5.56%10.20%10.55%						
MedicationPacemaker%%3.85%9.09%ACE inhibitors36%38.46%36.36%ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors23.08%36.36%Statins32%23.08%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants37%26.092%27.27%Amiodarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Supraventricular15%4.17%12.55%Renal failure5%8.33%3.39%DecompensationOthers9%4.17%13.56%Infection10%13.56%10.61%Ischemic37%38.89%32.65%Chagas6%5.56%10.20%Valvular18%2.222%28.57%Idiopathic6%5.56%10.20%VHA classI9%3.03%9.52%II26%5.50%19.05%19.05%IV7%5.00%9.52%11.54%IS14%26%5.50%19.05%II26%5.00%9.52%18.82%II <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>						
MedicationACE inhibitors36%38.46%36.36%ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors22%23.08%36.36%Statins35%38.46%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amiodarone9%11.54%90%Digoxin3%3.85%30.3%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Lack of medication19%41.67%15.25%Renal failure5%8.33%3.96%Decompensation0thers13%27.78%MotiveUnknown10%13.56%10.61%Idiopathic6%5.56%10.20%Others13%27.78%16.33%EtiologyUnknown30%30.77%27.27%NYHA classI6%5.50%19.05%II26%5.50%19.05%11.7%HospitalizationIntensive care14%3.85%18.18%General ward86%96.15%81.82%CFS17%214%18%-<		Pacemaker				
ARBs27%30.77%27.27%Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors21%7.69%13.64%Aspirin32%23.08%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amiodarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.22%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Supraventricular4.17%10.20%13.56%Infection19%4.167%15.25%Renal failure5%8.33%3.99%Decompensation0thers9%4.17%13.56%Infection10%13.56%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Valvular18%22.22%28.57%II60%30.00%68.25%II6%5.60%10.20%VHA classI17%43.5%IS11%9%5.00%9.52%II6%5.60%10.20%Valvular86%96.15%81.82%EtiologyIntensive care14%38.5%18.18%II11%5%10.00%3	Medication	ACE inhibitors	36%			
Beta blockers60%69.23%57.58%Mineralocorticoid receptor24%26.92%24.24%inhibitors24%26.92%24.24%Calcium channel blockers12%23.08%36.36%Statins32%23.08%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amiodarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.7%Supraventriculartachycardia15%4.17%15.25%Renal failure5%8.33%3.39%Decompensation0thers9%4.17%15.66%motiveUnknown10%13.56%10.61%Ischemic37%38.89%32.65%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Others13%27.78%16.33%EtiologyUnknown30%30.77%27.27%NYHA classI6%5.56%10.20%II66%5.56%10.20%19.05%IV5%10.00%31.7%HospitalizationIntensive care14%3.85%81.82%CFS1214% <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>						
Mineralocorticoid receptor inhibitors24%26.92%24.24%Calcium channel blockers12%7.69%13.64%Aspirin32%23.08%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amiodarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%41.67%15.25%Renal failure5%8.33%3.39%Decompensation0thers9%4.17%13.56%motiveUnknown10%13.56%10.61%Ischemic37%38.89%32.65%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Valvular18%22.22%28.57%II60%30.00%68.25%II60%30.00%68.25%II26%5.56%10.20%VV5%10.00%3.17%HospitalizationIntensive care14%3.85%81.82%CFS1214%332%4332%59%610%30%9.50%81.82%<		Beta blockers				
Aspirin32%23.08%36.36%Statins35%38.46%36.36%Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amiodarone9%11.54%900%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Lack of medication9%8.33%10.17%Lack of medication9%4.17%15.25%Renal failure5%8.33%3.39%Decompensation10%13.56%10.61%motiveUnknown10%13.56%10.20%Unknown10%13.56%10.20%Chagas6%5.56%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Valvular18%22.22%28.57%Ili9%5.00%9.52%II60%30.00%68.25%III60%30.00%68.25%IV5%10.00%3.17%HospitalizationIntensive care14%3.85%81.82%CFS17%214%18%332%32%332%9%610%9%		Mineralocorticoid receptor	24%			
Statins 35% 38.46% 36.36% Furosemide 49% 42.31% 48.48% Anticoagulants 27% 26.92% 27.27% Amiodarone 9% 11.54% 9.09% Digoxin 3% 3.85% 3.03% Progression 22% 29.17% 25.42% Non-adherence to diet 11% 4.17% 10.17% Lack of medication 9% 8.33% 10.17% Supraventricular		Calcium channel blockers	12%	7.69%	13.64%	
Furosemide49%42.31%48.48%Anticoagulants27%26.92%27.27%Amiodarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Supraventricular15%4.17%22.03%Infection19%41.67%15.25%Renal failure5%8.33%3.39%Decompensation0thers9%4.17%13.56%MotiveUnknown10%13.56%10.61%Ischemic37%38.89%32.65%10.20%Chagas6%5.56%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Others13%27.78%16.33%EtiologyUnknown30%30.77%27.27%NYHA classI9%5.00%9.52%II60%30.00%68.25%III26%55.00%19.05%IV5%10.00%3.17%Hospitalization11%4%385%18.18%CFS17%214%18%332%9%418%28%5.0%9%-59%332%9% <t< td=""><td></td><td>Aspirin</td><td>32%</td><td>23.08%</td><td>36.36%</td></t<>		Aspirin	32%	23.08%	36.36%	
Anticoagulants27%26.92%27.27%Amiodarone9%11.54%9.09%Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%41.67%15.25%Supraventricular15%4.17%22.03%Infection19%41.67%15.25%Renal failure5%8.33%3.39%Decompensation0thers9%4.17%13.56%motiveUnknown10%13.56%10.61%Ischemic37%38.89%32.65%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Valvular18%22.22%28.57%Ili6%5.00%9.52%Ili6%5.00%9.52%Ili6%5.00%9.52%Ili6%5.00%19.05%IV5%10.00%3.17%HospitalizationIntensive care14%3.85%General ward86%96.15%81.82%CFS112%332%332%33 <td></td> <td>Statins</td> <td>35%</td> <td>38.46%</td> <td>36.36%</td>		Statins	35%	38.46%	36.36%	
Amiodarone 9% 11.54% 9.09% Digoxin 3% 3.85% 3.03% Progression 22% 29.17% 25.42% Non-adherence to diet 11% 4.17% 10.17% Lack of medication 29% 8.33% 10.17% Supraventricular tachycardia 15% 4.17% 22.03% Infection 19% 41.67% 15.25% Renal failure 5% 8.33% 3.39% Decompensation Others 9% 4.17% 13.56% Monovn 10% 13.56% 10.61% Ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Itili 9% 5.00% 9.52% III 60% 30.00% 68.25% IV <		Furosemide	49%	42.31%	48.48%	
Digoxin3%3.85%3.03%Progression22%29.17%25.42%Non-adherence to diet11%4.17%10.17%Lack of medication9%8.33%10.17%Supraventricular15%4.17%22.03%Infection19%41.67%15.25%Renal failure5%8.33%3.39%Decompensation0thers9%4.17%13.56%motiveUnknown10%13.56%10.61%Echemic37%38.89%32.65%Chagas6%5.56%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Others13%27.78%16.33%EtiologyUnknown30%30.77%27.27%NYHA classI9%5.00%9.52%II60%30.00%68.25%10.00%IV5%10.00%3.17%HospitalizationIntensive care14%3.85%18.18%CFS17%214%18%332%32%418%59%610%9%79%810%9%610% <trr>79%<!--</td--><td></td><td>Anticoagulants</td><td>27%</td><td>26.92%</td><td>27.27%</td></trr>		Anticoagulants	27%	26.92%	27.27%	
Progression 22% 29.17% 25.42% Non-adherence to diet 11% 4.17% 10.17% Lack of medication 9% 8.33% 10.17% Supraventricular 15% 4.17% 22.03% Infection 19% 41.67% 15.25% Renal failure 5% 8.33% 3.39% Decompensation Others 9% 4.17% 13.56% motive Unknown 10% 13.56% 10.20% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.07% 22.27% NYHA class I 9% 5.00% 9.52% III 60% 30.00% 68.25% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85%		Amiodarone	9%	11.54%	9.09%	
Non-adherence to diet 11% 4.17% 10.17% Lack of medication 9% 8.33% 10.17% Supraventricular 15% 4.17% 22.03% Infection 19% 41.67% 15.25% Renal failure 5% 8.33% 3.39% Decompensation Others 9% 4.17% 13.56% Infection 10% 13.56% 10.61% Ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.07% 27.27% NYHA class I 9% 5.00% 9.52% II 60% 30.00% 68.25% IUN 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18%<		Digoxin	3%	3.85%	3.03%	
Lack of medication Supraventricular9%8.33%10.17%Supraventricular15%4.17%22.03%tachycardia15%4.17%15.25%Infection19%41.67%15.25%Renal failure5%8.33%3.39%Decompensation motive0thers9%4.17%13.56%Unknown10%13.56%10.61%Ischemic37%38.89%32.65%Chagas6%5.56%10.20%Valvular18%22.22%28.57%Idiopathic6%5.56%10.20%Others13%27.78%16.33%EtiologyUnknown30%30.77%27.27%NYHA classI9%5.00%9.52%II60%30.00%68.25%III26%55.00%19.05%IV5%10.00%3.17%HospitalizationIntensive care14%3.85%IR7%214%332%418%59%610%59%610%79%610%610%79%610%610%79%		Progression	22%	29.17%	25.42%	
Supraventricular 15% 4.17% 22.03% Infection 19% 41.67% 15.25% Renal failure 5% 8.33% 3.39% Decompensation 0thers 9% 4.17% 15.25% motive Unknown 10% 13.56% 10.61% ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% III 60% 30.00% 68.25% INF 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% CFS 1 7% - - 2 14% 18% -		Non-adherence to diet	11%	4.17%	10.17%	
iachycardia 15% 4.17% 22.03% Infection 19% 41.67% 15.25% Renal failure 5% 8.33% 3.39% Decompensation Others 9% 4.17% 15.25% motive Unknown 10% 13.56% 10.61% ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% III 60% 30.00% 68.25% INF 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - <		Lack of medication	9%	8.33%	10.17%	
Infection 19% 41.67% 15.25% Renal failure 5% 8.33% 3.39% Decompensation Others 9% 4.17% 13.56% motive Unknown 10% 13.56% 10.61% Ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% III 60% 30.00% 68.25% III 60% 30.00% 68.25% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 81.82% CFS 1 7% - - 2 14% 18% - - <td></td> <td>Supraventricular</td> <td></td> <td></td> <td></td>		Supraventricular				
Renal failure 5% 8.33% 3.39% Decompensation Others 9% 4.17% 13.56% motive Unknown 10% 13.56% 10.61% lschemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% III 60% 30.00% 68.25% III 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 38.5% 18.82% CFS 1 7% - - 3 32% - - - </td <td></td> <td>tachycardia</td> <td>15%</td> <td>4.17%</td> <td>22.03%</td>		tachycardia	15%	4.17%	22.03%	
Decompensation Others 9% 4.17% 13.56% motive Unknown 10% 13.56% 10.61% Ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% II 9% 5.00% 9.52% III 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 3 32% - - - <td></td> <td>Infection</td> <td>19%</td> <td>41.67%</td> <td>15.25%</td>		Infection	19%	41.67%	15.25%	
motive Unknown 10% 13.56% 10.61% Ischemic 37% 38.89% 32.65% Ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% II 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 3 32% - - - 5 9% - - -		Renal failure	5%	8.33%	3.39%	
Ischemic 37% 38.89% 32.65% Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% III 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% CFS 1 7% - - 2 14% 3.85% 18.18% CFS 1 7% - - 3 322% - - - 3 32% - - - 5 9% - - - 5 9% <td>Decompensation</td> <td>Others</td> <td>9%</td> <td>4.17%</td> <td>13.56%</td>	Decompensation	Others	9%	4.17%	13.56%	
Chagas 6% 5.56% 10.20% Valvular 18% 22.22% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 50.00% 9.52% II 9% 50.00% 9.52% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 3 32% - - - 5 9% - - - 5 9% - - - 6 10% - - - 1 1 - - - 2 <t< td=""><td>motive</td><td>Unknown</td><td></td><td>13.56%</td><td>10.61%</td></t<>	motive	Unknown		13.56%	10.61%	
Valvular 18% 22.2% 28.57% Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 500% 9.52% II 60% 30.00% 68.25% III 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% CFS 1 7% - - 2 14% .86% 96.15% 81.82% CFS 1 7% - - 3 32% - - - 5 9% - - - 5 9% - - - 6 10% - - 7 9% <td></td> <td></td> <td>37%</td> <td>38.89%</td> <td>32.65%</td>			37%	38.89%	32.65%	
Idiopathic 6% 5.56% 10.20% Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% IN 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 3 32% - - - 4 18% - - - 5 9% - - - 5 9% - - - 6 10% - - - 7 9% - - -				5.56%	10.20%	
Others 13% 27.78% 16.33% Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% II 60% 30.00% 68.25% III 60% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 3 32% - - 4 18% - - 5 9% - - 5 9% - - 66 10% - - 7 9% - - 88 1% - -		Valvular	18%	22.22%		
Etiology Unknown 30% 30.77% 27.27% NYHA class I 9% 5.00% 9.52% II 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 3 32% - - - 4 18% - - - 5 9% - - - 5 9% - - - 5 9% - - - 6 10% - - - 7 9% - - - 8 1% - - -						
NYHA class I 9% 5.00% 9.52% II 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 3 32% - - - 4 18% - - - 5 9% - - - 5 9% - - - 5 9% - - - 6 10% - - - 7 9% - - - 8 1% - - -						
II 60% 30.00% 68.25% III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 2 14% - - - 3 32% - - - 5 9% - - - 6 10% - - - 7 9% - - - 8 1% - - -						
III 26% 55.00% 19.05% IV 5% 10.00% 3.17% Hospitalization Intensive care 14% 3.85% 18.18% General ward 86% 96.15% 81.82% CFS 1 7% - - 2 14% - - 3 32% - - 4 18% - - 5 9% - - 6 10% - - 7 9% - - 8 1% - -	NYHA class					
IV 5% 10.00% 3.17% Hospitalization Intensive care General ward 14% 3.85% 18.18% CFS 1 7% - - 2 14% - - 3 32% - - 4 18% - - 5 9% - - 6 10% - - 7 9% - - 8 1% - -						
Hospitalization Intensive care General ward 14% 3.85% 18.18% CFS 1 7% - - 2 14% - - 3 32% - - 4 18% - - 5 9% - - 6 10% - - 7 9% - - 8 1% - -						
General ward 86% 96.15% 81.82% CFS 1 7% - - 2 14% - - 3 32% - - 4 18% - - 5 9% - - 6 10% - - 7 9% - - 8 1% - -						
CFS 1 7% - - 2 14% - - 3 32% - - 4 18% - - 5 9% - - 6 10% - - 7 9% - - 8 1% - -	Hospitalization					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	050					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	CFS				-	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$					-	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$						
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				-	-	
7 9% – – 8 1% – –				-	-	
8 1%				-	-	
				-	-	
J U/a – –				-	_	
Mortality In-hospital 10.2% 8.00% 7.69%	Mortality			- 8 00%	- 7 60%	
1-year 40.96% 59.09% 29.09%	wortancy	-				
1 year		cui	10,00/0	55.05%	20,00/0	

4. Discussion

HF and frailty are closely related, both in their pathogenesis and impact on prognosis. They are systemic syndromes, in which inflammation has been well established as contributing to their development, adverse prognosis and progression. High levels of inflammatory markers in HF patients (IL-6, CRP and TNF alpha) have been associated with muscle loss, cardiac cachexia and declining physical function, factors known




Fig. 2. 1-year mortality per CFS.

to play an important role in frailty [18]. Simultaneously, frail patients show elevated levels of inflammation markers: white blood cells, interleukin 6, C-reactive protein, factor VIII, fibrinogen and D-dimer [19]. Also, endothelial dysfunction can contribute to worse outcomes in HF, and the analysis of results from the Toledo Study for Healthy Aging revealed that endothelial function is impaired in frail patients [20]. Age alone is recognized to contribute to cardiovascular disease, since senescent cardiomyocytes are characterized by prolonged relaxation, diminished contraction velocity, a decrease in *β*-adrenergic response, and increased myocardial stiffness [21]. Cardiac changes with chronological aging are multiple (increased vasoconstriction and impaired vasodilatation, increased atherosclerosis, reduced vasodilatory capacity, impaired microvascular function, increased left ventricular mass and stiffness, increased prevalence of atrial fibrillation) [22], but they seem not to explain on their own the worst prognosis associated with biological aging or frailty.

In this study, we demonstrated that frailty is an independent prognostic factor for 1-year mortality, using a simple and fast scale for its assessment. These findings are similar to several others reported in the past. The FRAIL-HF study evaluated frailty in 450 patients admitted because of acute heart failure in Spain [23]. It used the Freid criteria to determine frailty status, and found it was significantly associated with 1year all-cause mortality (HR = 2.13; 95% CI = 1.07–4.23). Another study performed in the United Kingdom in 265 hospitalized heart failure patients showed that the addition of the CFS to a predictive model enhanced its performance compared with a base model. It also showed that frailty is related to the nutritional status [24]. In Japan, the frailty of 181 patients was retrospectively assessed after discharge by means of




Fig. 3. Adjusted mortality odds ratio.

grip strength and performance measures. During 2 years of follow up, subjects who met all the criteria had a 4 times greater risk of cardiac events compared with those with no frailty criteria [25]. Finally, in the USA, a cohort of 56 consecutive hospitalized HF patients showed a higher risk for 6-month readmission or mortality if they had a weak grip and cognitive impairment [26].

Unfortunately, there is no validated tool to assess frailty in HF patients. A systematic review showed that, in 20 studies published in 24 articles, 7 different instruments were used [27]. The most frequently used was Fried's Frailty Phenotype, followed by the Comprehensive Geriatric Assessment. Only 5 of the 20 identified studies evaluated hospitalized patients due to acute HF, and most investigated chronic or advanced heart failure patients.

Since the most common used instruments to assess frailty are timeconsuming and require special knowledge or instruments, we intended to determine the performance of a simple and fast instrument for the risk assessment of hospitalized HF patients. The CFS can be calculated by the attending physician in a matter of seconds and has some advantages over simply "eye-balling" the patient; it establishes a numerical value (however subjective), and it compels the physician to thoroughly consider his patient's frailty status. No HF risk assessment tool considers frailty as a prognostic factor, but there is enough evidence that it is strongly and independently related to hard outcomes. It should be accounted for in future risk models, and in the meantime implemented in everyday clinical practice.

The principal limitations of this study are the small sample size that did not allow the evaluation of multiple outcomes, and the lack of comparison with other frailty assessment tools. Also, because it was done in a single center with high-risk patients, its results should be considered with caution before extrapolating to the general population.

5. Conclusion

Frailty was associated with a 2-fold increase in the in 1-year mortality risk after a hospitalization due to acute heart failure. It was assessed with the CFS, which can be implemented easily in clinical practice. It should be considered in future risk models, since it is independently linked to worse outcomes.

Conflicts of interest

None declared.

Acknowledgements

We thank Dr. Martín Garré and Dr. Alejo A. Pérez de la Hoz for their assistance during data collection, as well as all the attending physicians and participating patients.

References

- P. Ponikowski, S.D. Anker, K.F. Al Habib, et al., Heart failure: preventing disease and death worldwide, ESC Heart Fail. 1 (2014) 4–25.
- [2] D. Mozaffarian, E.J. Benjamin, A.S. Go, et al., American Heart Association Statistics Committee; Stroke Statistics Subcommittee, Heart disease and stroke Statistics-2016 update: a report from the American Heart Association, Circulation 133 (2016) e38–e360.

- [3] D. Levy, S. Kenchaiah, M.G. Larson, et al., Long-term trends in the incidence of and survival with heart failure, N. Engl. J. Med. 347 (2002) 1397–1402.
- [4] S.R. Jha, H.S. Ha, L.D. Hickman, et al., Frailty in advanced heart failure: a systematic review, Heart Fail. Rev. 20 (2015) 553–560.
- [5] J. Kulmala, I. Nykanen, S. Hartikainen, Frailty as a predic- tor of all-cause mortality in older men and women, Geriatr Gerontol Int 14 (2014) 899–905.
- [6] K. Rockwood, S.E. Howlett, C. MacKnight, et al., Prevalence, attributes, and outcomes of fitness and frailty in community- dwelling older adults: report from the Canadian study of health and aging, J. Gerontol. A Biol. Sci. Med. Sci. 59 (2004) 1310–1317.
- [7] L.P. Fried, C.M. Tangen, J. Walston, A.B. Newman, C. Hirsch, J. Gottliener, et al., Frailty in older adults evidence for a phenotype, J. Gerontol. Ser. A Biol. Sci. Med. Sci. 56 (3) (2001) M146–M157.
- [8] S. Altimir, J. Lupon, B. Gonzalez, M. Prats, T. Parajon, A. Urrutia, et al., Sex and age differences in fragility in a heart failure population, Eur. J. Heart Fail. 7 (5) (2005) 798–802.
- [9] K. Rockwood, et al., A global clinical measure of fitness and frailty in elderly people, CMAJ 173 (2005) 489–495.
- [10] I. Uchmanowicz, M. Łoboz-Rudnicka, Szeląg P, Jankowska-Polańska B, Łoboz-Grudzień K. Frailty in heart failure, Curr. Heart Fail. Rep. 11 (3) (2014) 266–273.
- [11] S. Volpato, M. Cavalieri, F. Sioulis, et al., Predictive value of the short physical performance battery following hospitali- zation in older patients, J. Gerontol. A Biol. Sci. Med. Sci. 66 (2011) 89–96.
- [12] J. Lupon, B. Gonzalez, S. Santaeugenia, S. Altimir, A. Urrutia, D. Mas, et al., Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure, Rev. Esp. Cardiol. 61 (8) (2008) 835–842.
- [13] F. Cacciatore, P. Abete, F. Mazzella, L. Viati, D. Della Morte, D. D'Ambrosio, et al., Frailty predicts long-term mortality in elderly subjects with chronic heart failure, Eur. J. Clin. Investig. 35 (12) (2005) 723–730, https://doi.org/10.1111/j.1365-2362. 2005.01572.x ([Internet], Available from:).
- [14] S.M. McNallan, A.M. Chamberlain, Y. Gerber, M. Singh, R.L. Kane, S.A. Weston, et al., Measuring frailty in heart failure: a community perspective, Am. Heart J. 166 (4) (2013) 768–774.
- [15] SJ. Pocock, C.A. Ariti, J.J. McMurray, A. Maggioni, L. Kober, I.B. Squire, K. Swedberg, J. Dobson, K.K. Poppe, G.A. Whalley, R.N. Doughty, Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies, Eur. Heart J. 34 (2013) 1404–1413.
- [16] W.C. Levy, D. Mozaffarian, D.T. Linker, S.C. Sutradhar, S.D. Anker, A.B. Cropp, I. Anand, A. Maggioni, P. Burton, M.D. Sullivan, B. Pitt, P.A. Poole-Wilson, D.L. Mann, M. Packer, The Seattle heart failure model: prediction of survival in heart failure, Circulation 113 (2006) 1424–1433.
- [17] Ben Jann, Plotting regression coefficients and other estimates, Stata J. 14 (4) (2014) 708–737.
- [18] S.D. Anker, S. von Haehling, Inflammatory mediators in chronic heart failure: an overview, Heart 90 (4) (2004) 464–470.
- [19] J. Walston, M.A. McBurnie, A. Newman, R.P. Tracy, W.J. Kop, C.H. Hirsch, et al., Frailty and activation of the inflammation and coagula- tion systems with and without clinical comorbidities: results from the cardiovascular health study, Arch. Intern. Med. 162 (2002) 2333–2341.
- [20] C. Alonso-Bouzon, L. Carcaillon, F.J. Garcia-Garcia, M.S. Amor-Andres, M. El Assar, L. Rodriguez-Manas, Association between endo- thelial dysfunction and frailty: the Toledo study for healthy aging, Age 20 (2013) 20.
- [21] E.G. Lakatta, D. Levy, Arterial and cardiac aging: major sharehold- ers in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease, Circulation 107 (2003) 346–354.
- [22] S. Nanayakkara, T.H. Marwick, D.M. Kaye, The ageing heart: the systemic and coronary circulation, Heart 104 (5) (2018) 370–376.
- [23] M.T. Vidan, V. Blaya-Novakova, E. Sanchez, et al., Prevalence and prognostic impact of frailty and its components in non- dependent elderly patients with heart failure, Eur. J. Heart Fail. 18 (2016) 869–875.
- [24] S. Sze, J. Zhang, P. Pellicori, D. Morgan, A. Hoye, A.L. Clark, Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction, Clin. Res. Cardiol. 106 (7) (2017) 533–541.
- [25] S. Yamada, K. Kamiya, Y. Kono, Frailty may be a risk marker for adverse outcome in patients with congestive heart failure, ESC Heart Fail. 2 (3) (2015) 168–170.
- [26] E. Joyce, E.H. Howell, A. Senapati, R.C. Starling, E.Z. Gorodeski, Prospective assessment of mini-cog and grip strength identifies hospitalized heart failure patients at increased, Circulation 134 (2016).
- [27] J. McDonagh, L. Martin, C. Ferguson, S.R. Jha, P.S. Macdonald, P.M. Davidson, et al., Frailty assessment instruments in heart failure: a systematic review, Eur. J. Cardiovasc. Nurs. 17 (1) (2018) 23–35.